Completed Antibody Panels
Panel size: | 14 antibodies |
Validated tissue type(s): | Fresh frozen human head and neck squamous cell carcinoma (HNSCC) tissue |
1 | CD45 |
2 | CD4 |
3 | CD8 |
4 | HLA-DR |
5 | Pan-Cytokeratin |
6 | Ki67 |
7 | CD11c |
8 | CD31 |
9 | CD19 |
10 | CD69 |
11 | CD104 |
12 | PD-1 (CD279) |
13 | CD38 |
14 | CD3 |
Panel size: | 14 antibodies |
Validated tissue type(s): | FFPE human renal cell carcinoma (RCC) |
FFPE human tonsil |
1 | CD45 |
2 | CD4 |
3 | CD8 |
4 | HLA-DR |
5 | Pan-Cytokeratin |
6 | Ki67 |
7 | CD11c |
8 | CD31 |
9 | CD20 |
10 | CD68 |
11 | CD107a |
12 | Podoplanin |
13 | TFAM |
14 | CD3e |
Panel size: | 24 antibodies | |
Validated tissue type(s): | FFPE human breast tissue (normal, DCIS, invasive carcinoma) | |
FFPE human tonsil |
1 | CD45 | 15 | HLA-A |
2 | CD4 | 16 | CD56 |
3 | CD8 | 17 | CD45RO |
4 | HLA-DR | 18 | GATA3 |
5 | Pan-Cytokeratin | 19 | ERα |
6 | Ki67 | 20 | Keratin8/18 |
7 | CD11c | 21 | Keratin5 |
8 | PD-L1 | 22 | HER2 |
9 | CD20 | 23 | PR |
10 | CD68 | 24 | AR |
11 | CD107a | ||
12 | FOXP3 | ||
13 | Granzyme B | ||
14 | CD163 |
Antibodies labeled in green are not available from Akoya Biosciences and were conjugated to barcodes by the ITR. |
The ITR has successfully used the above panels on the indicated tissue types.
Please note that antibody clones used on fresh frozen tissue are different from those used on FFPE tissue, so panels developed on one sample type may not be used on the other. If you want to use the above panels on tissue types not listed above, we will need to optimize the panel for your tissue (e.g. re-titrate antibodies, incorporate a tissue autofluorescence quenching protocol).
We are looking forward to taking on new projects and developing more panels in the future.
If you would like to see Akoya Biosciences’ current catalog of pre-conjugated antibodies, please click the following link and view the section labeled “PhenoCycler Antibodies:”
https://www.akoyabio.com/phenocycler/assays/
We also provide a conjugation service for antibodies against targets which are not listed in the catalog. The major requirement for conjugation is that the antibody is monoclonal. Ideally, the antibody should also be compatible with immunohistochemistry (IHC). To validate the antibody, we will use the unconjugated antibody in chromogenic IHC and compare its staining pattern to the conjugated antibody’s staining pattern in the PhenoCycler images.
PhenoCycler (CODEX) Technology
|